JP2008531647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531647A5 JP2008531647A5 JP2007557486A JP2007557486A JP2008531647A5 JP 2008531647 A5 JP2008531647 A5 JP 2008531647A5 JP 2007557486 A JP2007557486 A JP 2007557486A JP 2007557486 A JP2007557486 A JP 2007557486A JP 2008531647 A5 JP2008531647 A5 JP 2008531647A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- preparation according
- oligodeoxyribonucleotide
- formulation
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920000272 Oligonucleotide Polymers 0.000 claims 5
- 230000000259 anti-tumor Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960004120 defibrotide Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (12)
- 抗腫瘍作用を有する製剤であって、該製剤が、4000-10000ダルトンの分子量を有し且つ+30°および+46.2°の間の比旋光度を有するオリゴデオキシリボヌクレオチドを含む、上記製剤。
- 該オリゴデオキシリボヌクレオチドが以下の分析パラメーターを有することを特徴とする、請求項1に記載の製剤。
h(濃色効果) <10
A+T/C+G:1.100-1.455
A+G/C+T:0.800-1.160 - 該オリゴデオキシリボヌクレオチドが、動物および/または植物の組織からの抽出により得られたものであることを特徴とする、請求項1に記載の製剤。
- 該オリゴデオキシリボヌクレオチドが、合成的に得られることを特徴とする、請求項1に記載の製剤。
- 該製剤が哺乳動物に投与されるものであることを特徴とする、請求項1に記載の製剤。
- 該哺乳動物がヒトであることを特徴とする、請求項5に記載の製剤。
- 該製剤が静脈から投与されるものであることを特徴とする、請求項1に記載の製剤。
- 該製剤が水溶液であることを特徴とする、請求項1に記載の製剤。
- 該製剤が抗腫瘍作用を有する少なくとも1の他の活性成分を含むことを特徴とする、請求項1に記載の製剤。
- 抗腫瘍作用を有する該他の活性成分が、デフィブロチド、ラパマイシン、パクリタキセル、モノクロタリン、BCNU、および/またはシクロホスファミドから選択されることを特徴とする、請求項9に記載の製剤。
- 該製剤が慣用の賦形剤および/またはアジュバンドを含むことを特徴とする、請求項1に記載の製剤。
- 該オリゴデオキシリボヌクレオチドが、哺乳動物の器官からの抽出により得られたものであることを特徴とする、請求項1に記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000336A ITMI20050336A1 (it) | 2005-03-03 | 2005-03-03 | Formulazione ad attivita' anti-tumorale |
US73140405P | 2005-10-28 | 2005-10-28 | |
PCT/EP2006/060306 WO2006094917A2 (en) | 2005-03-03 | 2006-02-27 | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531647A JP2008531647A (ja) | 2008-08-14 |
JP2008531647A5 true JP2008531647A5 (ja) | 2009-04-02 |
Family
ID=36572331
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび/またはオリゴデオキシリボヌクレオチド |
JP2007557486A Pending JP2008531647A (ja) | 2005-03-03 | 2006-02-27 | 抗腫瘍作用を有する製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび/またはオリゴデオキシリボヌクレオチド |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080194507A1 (ja) |
EP (2) | EP1855697A2 (ja) |
JP (2) | JP5714203B2 (ja) |
KR (3) | KR20070120953A (ja) |
AU (2) | AU2006222044A1 (ja) |
CA (2) | CA2598072C (ja) |
IL (3) | IL185181A0 (ja) |
MX (2) | MX2007010407A (ja) |
WO (2) | WO2006094917A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
US8187897B2 (en) | 2008-08-19 | 2012-05-29 | International Business Machines Corporation | Fabricating product chips and die with a feature pattern that contains information relating to the product chip |
JP6069209B2 (ja) | 2010-11-12 | 2017-02-01 | ジェンティウム ソシエタ ア レスポンサビリタ リミタータ | 移植片対宿主病(gvhd)の予防および/または治療に使用するためのデフィブロタイド |
RU2627177C2 (ru) | 2012-06-22 | 2017-08-03 | Джентиум С.Р.Л. | Способ определения биологической активности дефибротида, основанный на применении эуглобулина |
EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
JP2020530004A (ja) | 2017-08-03 | 2020-10-15 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 核酸を高濃度で含む製剤 |
WO2019200251A1 (en) | 2018-04-12 | 2019-10-17 | Jazz Pharmaceuticals, Inc. | Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion |
US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
WO2022234101A1 (en) | 2021-05-06 | 2022-11-10 | Jazz Pharmaceuticals Ireland Limited | Defibrotide for the treatment and prevention of acute respiratory distress syndrome |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
CA2259041A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
EP0985035A2 (en) * | 1997-05-30 | 2000-03-15 | McGILL UNIVERSITY | Dna methyltransferase genomic sequences and antisense oligonucleotides |
DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
-
2006
- 2006-02-27 JP JP2007557485A patent/JP5714203B2/ja not_active Expired - Fee Related
- 2006-02-27 KR KR1020077021110A patent/KR20070120953A/ko not_active Application Discontinuation
- 2006-02-27 AU AU2006222044A patent/AU2006222044A1/en not_active Abandoned
- 2006-02-27 KR KR1020077023861A patent/KR20070121001A/ko not_active Application Discontinuation
- 2006-02-27 EP EP06708537A patent/EP1855697A2/en not_active Withdrawn
- 2006-02-27 EP EP06708536A patent/EP1853277A1/en not_active Ceased
- 2006-02-27 US US11/817,575 patent/US20080194507A1/en not_active Abandoned
- 2006-02-27 CA CA2598072A patent/CA2598072C/en not_active Expired - Fee Related
- 2006-02-27 CA CA002598613A patent/CA2598613A1/en not_active Abandoned
- 2006-02-27 AU AU2006222045A patent/AU2006222045B2/en not_active Ceased
- 2006-02-27 MX MX2007010407A patent/MX2007010407A/es not_active Application Discontinuation
- 2006-02-27 WO PCT/EP2006/060306 patent/WO2006094917A2/en active Application Filing
- 2006-02-27 WO PCT/EP2006/060304 patent/WO2006094916A1/en active Application Filing
- 2006-02-27 JP JP2007557486A patent/JP2008531647A/ja active Pending
- 2006-02-27 MX MX2007010754A patent/MX2007010754A/es not_active Application Discontinuation
- 2006-02-27 KR KR1020077021114A patent/KR20070120954A/ko not_active Application Discontinuation
- 2006-02-27 US US11/817,572 patent/US20080194506A1/en not_active Abandoned
-
2007
- 2007-08-09 IL IL185181A patent/IL185181A0/en unknown
- 2007-08-09 IL IL185182A patent/IL185182A0/en active IP Right Grant
- 2007-08-14 IL IL185258A patent/IL185258A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008531647A5 (ja) | ||
JP2008531646A5 (ja) | ||
CY1119839T1 (el) | Στερεες μορφες δοσεως μπενταμουστινης | |
WO2009126950A3 (en) | Diterpene glycosides as natural solubilizers | |
WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
CN105055642A (zh) | 一种复方胍类消毒剂及其制备方法 | |
EP2455085A3 (en) | Use of at least one compound of the family of the avermectins or of the family of the milbemycins in the treatment of ophthalmic pathologies | |
JP2009539991A5 (ja) | ||
WO2011015634A3 (en) | Controlled release formulations of lipocalin muteins | |
EP2147927A3 (en) | Use of 131i-tm-601 for the diagnosis and treatment of gliomas | |
WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
WO2010030704A3 (en) | Antibacterial aminoglycoside analogs | |
EP2548552A3 (en) | Titration package for 1-amino-alkylcylohexanes | |
JP2019511558A5 (ja) | ||
WO2010147430A3 (en) | Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same | |
WO2008149802A1 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
WO2009026473A3 (en) | Stabilized therapeutic compositions and formulations | |
JP2012508256A5 (ja) | ||
WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
JP2007504194A5 (ja) | ||
WO2015152577A2 (ko) | 골 질환 예방 및 치료용 조성물 | |
JP2012526099A5 (ja) | ||
JP2014504628A5 (ja) | ||
JP2009137951A5 (ja) |